What happened
ClinicalTrials.gov first posted NCT07932262 on 12 November 2026. The sponsor is University Hospital Tübingen in Germany. This is a single-centre, open-label Phase 1/2 study with one treatment group. It tests UKT-CART19.1, CAR-T cells made from the person's own T cells and aimed at CD19, a marker on B cells. The same treatment, given as one infusion, is tested in adults aged 18 to 80 with seven relapsed or treatment-resistant autoimmune diseases, one of which is multiple sclerosis (MS). People with MS must have had recent disease activity (a relapse, worsening or new MRI activity in the previous 24 months) and must not have responded to at least two high-potency MS medicines (category 3 in the German guideline). The registry estimates 36 participants in total for all diseases and does not say how many will have MS. The main outcome is safety over 6 months. The EU clinical trials register (CTIS) shows authorisation in Germany on 14 August 2026. ClinicalTrials.gov lists the study as not yet accepting participants, with an estimated start in January 2027.
What this means for people with MS
Registration and authorisation describe a study plan. They do not show that anyone has been enrolled or treated, or that UKT-CART19.1 works or is safe in MS, and no results are posted. The estimated start differs between the two records (recruitment from 1 July 2026 in CTIS, January 2027 on ClinicalTrials.gov), and neither shows that recruitment has begun. The study has one centre, in Tübingen, and neither record lists a site in Greece, so it is not an established route to treatment for people in Greece. Eligibility is decided by the study team, whose contacts are in the registry. Participants are to be followed for up to 15 years, as required for gene-therapy studies.
- What kind of evidence exists?
- ClinicalTrials.gov registration NCT07932262, first posted 12 November 2026, and the EU clinical trials register (CTIS) record of the same study
- How reliable is this source?
- Official ClinicalTrials.gov record and EU Clinical Trials Information System record of the same study. They document the design and the listed status, not results or actual treatment.
- Research event/source date
- Published by MyelinWatch
- Last substantive MyelinWatch update